HomeResearch & Knowledgeback to Homeback to Research & KnowledgeConvertible bonds: Pricing and structuringback to

Case Study

Convertible bonds: Pricing and structuring

29 pages

November 2016

Reference: IMD-7-1826

A convertible bond is a hybrid security that not only retains most of the salient features of a debt instrument (such as a fixed coupon payment, priority over common stock when a company is in default, etc.), but also offers the upside potential associated with the underlying common stock. Convertible bondholders can in fact, at their discretion,, “convert” their debt instruments for a specifies number of shares of the company on expiration or any time before expiration as specified in the offer prospectus. The objective of this paper is to present a simple methodology that can be used to price convertible bonds, methodology that requires only some basics algebra knowledge.

Learning Objective

Pricing and structuring of a convertible bond.

Keywords

Finance, Binomial Pricing Model

Type

Published Sources

Available Languages

English

IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Keep reading

Video

Clee Medical: Making brain surgery safer

Swiss startup Clee Medical is revolutionizing brain surgery with real-time imaging technology that boosts precision, safety, and patient outcomes.

Entrepreneurship Innovation Technology Management

By Jim Pulcrano

in I by IMD

Article

The AI reskilling paradox: Slow down to get there faster

Unlock the four zones of AI readiness and discover why sandboxing is the smartest strategy for executive-led transformation.

The return of industrial policy, and what it means for global business

Industrial policy is reshaping global competitiveness, strategy, and innovation as governments pursue resilience, security, and growth.

Geopolitics

By Simon J. Evenett and Fernando Martín Espejo

in I by IMD

Article

Are you sick as a parrot? 4 ways to sharpen your language skills and become a more effective leader

Avoid soulless management speak. Learn how leaders can use authentic, engaging language to connect, motivate, and inspire their teams effectively.

Communication Culture Leadership Team Work-life Balance

By Peter J. Meyers

in I by IMD

Case Study

Chugai (C): Navigating the next century of global innovation

Strategy Mergers and Acquisitions Organizational Culture Global Business

By Kazuo Ichijo and Yunfei Feng

Case Study

Chugai (B): Alliance with Roche to be among the best

Strategy Mergers and Acquisitions Organizational Culture Global Business

By Kazuo Ichijo and Yunfei Feng

Article

Google vs LLM - The Future Of Search

Google may have escaped major penalties in a landmark search monopoly ruling, but will the search giant survive the rise of LLMs and changing user behavior?

By Didier Bonnet and Jialu Shan

in I by IMD

Article

Think you don’t play favorites? Think again

Are you unknowingly playing favorites at work? Take this quick test to uncover bias and learn proven strategies for fairer leadership.

General Management Leadership Team

By Ginka Toegel and Jean-Louis Barsoux

in I by IMD

Article

Think you don’t play favorites? Think again

Most managers like to think they act the same toward all their team members, but research says otherwise. Take the test below to check if you’re unconsciously playing favorites, and check out the tips on resolving the problem.

Leadership

By Ginka Toegel and Jean-Louis Barsoux

in I by IMD Brain Circuits

12 November 2025

Video

Christophe Fouquet - CEO of ASML

ASML CEO Christophe Fouquet shares how the company became Europe’s most indispensable tech firm and what’s next for EUV lithography innovation.

Leadership

By Jean-François Manzoni

in I by IMD

Clee Medical: Making brain surgery safer

By Jim Pulcrano
in I by IMD

Summary

Swiss startup Clee Medical is revolutionizing brain surgery with real-time imaging technology that boosts precision, safety, and patient outcomes.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Entrepreneurship

Innovation

Technology Management

Browse all topics

Are you sick as a parrot? 4 ways to sharpen your language skills and become a more effective leader

By Peter J. Meyers
in I by IMD

Summary

Avoid soulless management speak. Learn how leaders can use authentic, engaging language to connect, motivate, and inspire their teams effectively.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Communication

Culture

Leadership

Team

Work-life Balance

Browse all topics

Chugai (C): Navigating the next century of global innovation

By Kazuo Ichijo and Yunfei Feng
Case reference: IMD-2711 ©2025

Summary

Chugai C focuses on the company's future as it celebrates its 100th anniversary in 2025. In 2021, Chugai launched its ambitious 'TOP I 2030' growth strategy, aiming to transition from Japan's top innovator to a global leader. The strategy sets two primary targets: doubling RD output and launching one in-house global product annually by 2030. These goals are supported by three key drivers: a RED SHIFT toward early-stage research, comprehensive Digital Transformation DX, and Open Innovation. The case examines the progress made and the significant challenges that lie ahead. These include intense competition from firms in China and India, technological disruption from AI-driven drug discovery, geopolitical risks and cultural barriers to attracting global talent. The central question posed is whether Chugai's proven model for success can sustain its bid for global leadership in an era of unprecedented market shifts.

Reference IMD-2711

Organization Chugai Pharmaceutical

Industry Healthcare, Pharmaceuticals

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Strategy

Mergers and Acquisitions

Organizational Culture

Global Business

Browse all topics

Chugai (B): Alliance with Roche to be among the best

By Kazuo Ichijo and Yunfei Feng
Case reference: IMD-2710 ©2025

Summary

Chugai B examines the pivotal strategic alliance formed in October 2002 between Chugai Pharmaceutical and Swiss giant Roche. Facing constraints in RD funding and global reach, Chugai's President Osamu Nagayama sought a partnership to achieve the firm's ambition of becoming Japan's number one pharmaceutical enterprise while preserving its autonomy. The case examines the unique business model by which Roche acquired a 50.1 equity stake while Chugai retained its management, public listing and corporate identity. This structure created a powerful synergy: Chugai gained exclusive rights to develop and market Roche's innovative products in Japan, while Roche leveraged Chugai's RD pipeline for its global distribution network. The case details how the alliance transformed Chugai from Japan's 10th largest pharma firm into its market leader in oncology and by market capitalization by 2024. It provides a rich context for analyzing how strategic partnerships can bridge resource gaps, foster a 'capability revolution,' and accelerate a company's path to becoming a global innovation powerhouse.

Reference IMD-2710

Organization Chugai Pharmaceutical

Industry Healthcare, Pharmaceuticals

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Strategy

Mergers and Acquisitions

Organizational Culture

Global Business

Browse all topics